Galenus Group

Healthcare System Innovator & Research Institution
Advancing medicine through precision trials, longevity science & biotech. #ManagedCare #LifeSciences

[New York Post @nypost]

Veteran to become the first to receive new ‘hero’ bionic arm inspired by ‘Call of Duty’ https://t.co/BLj4Fcq1V2

[NEJM @NEJM]

Correspondence: CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis https://t.co/qNxDzOO2Sm

#Gastroenterology

[Galenus Group @GalenusGroup]

💖 Generational Legacy – Caring for our women today means building healthier, smarter, and stronger generations tomorrow. The quality of medical care and the innovations we place in our women’s hands will define the strength of our future. Women in America are stronger than ever — and this is only the beginning.

At Galenus, we’re not just adapting to the future — we’re building it. -Agosto @agostoresearch

#WomensHealth #InnovationInHealthcare #GalenusCare #FutureOfMedicine #GenerationalHealth

[Galenus Group @GalenusGroup]

🚀 Galenus Group Expands Its Clinical Research Pipeline

Over the past six months, we have significantly strengthened our research portfolio by partnering with some of the most innovative pharmaceutical and biotech companies in the world. These collaborations bring cutting-edge science to our sites in Puerto Rico and Florida, offering patients early access to groundbreaking therapies.

💡 New partners in our pipeline include:

Genentech – Pioneering biologics in inflammatory bowel disease (UC & Crohn’s)

Nkarta – Advancing NK cell immunotherapies in oncology

Gilead Sciences – Leading antiviral and metabolic research

Akero Therapeutics – Innovative approaches to MASH and liver health

Bio89 Bio – Targeted metabolic and cardiovascular therapies

Inventiva – Novel small-molecule therapies for metabolic and fibrotic diseases

📈 Strategic Impact:
These studies expand our footprint in gastroenterology, hepatology, immunology, and advanced cell therapies, aligning with Galenus Group’s vision to be a top-tier enroller in high-impact therapeutic areas. Our state-of-the-art facilities, expert PI network, and robust patient databases ensure rapid recruitment and operational excellence.
🌎 With each new partnership, we move closer to our mission: transforming patient outcomes through research that shapes the future of medicine.

#ClinicalResearch #Biotech #Pharma #GalenusGroup #InnovationInHealthcare #IBD #MASH #Oncology #Immunotherapy

[Galenus Group @GalenusGroup]

📊✨ At Galenus Group, we believe that data is more than numbers — it's insight, strategy, and transformation.

Our advanced reconciliation and analytics structures allow us to understand a provider before the first handshake. The data shows us who they are, where they’re thriving, and where they need support — even before we walk into their clinic.

Too often, providers operate blindly within their own practices. We equip them with the visibility to see what’s hidden, correct course, and thrive in value-based care.

This is not just innovation —
It’s the future of healthcare, and we’re building it every day.
#GalenusGroup #ValueBasedCare #HealthTech #AIinHealthcare #PrimaryCareTransformation #ClinicalInsights #HealthcareLeadership #FutureOfCare #PopulationHealth #DataDrivenDecisions #Palantir

[Galenus Group @GalenusGroup]

Beyond Traditional Healthcare

What sets us apart is our unique approach to finding the human story behind every chart and every challenge. We embrace complexity as an opportunity, bringing a distinctive blend of scientific rigor and market intuition.

Our interdisciplinary teams connect dots that others miss, identifying emerging trends in healthcare innovation before they become mainstream investment opportunities.

[Galenus Group @GalenusGroup]

The Human Element

At Galenus Group, we believe the most powerful insights come from understanding the human stories behind the data. Our approach integrates clinical expertise with financial acumen to identify solutions that create both economic and social value.

By connecting with patients, providers, and innovators, we develop a more nuanced understanding of healthcare needs and opportunities that purely quantitative analysis might miss.

[Galenus Group @GalenusGroup]

🌍🔬 At Galenus Group, we’re proud to be navigating the fascinating frontier of global markets, health innovation, and strategic investing!

As tariff dynamics shift and economic landscapes evolve, we’re not just observing — we’re positioning, responding, and leading.

💡 From biotech and clinical research to equity strategy and macro insights, we embrace complexity as opportunity. Our teams are analyzing trends, adapting to policy shifts, and finding the human story behind every chart and every challenge.

🚀 Whether it's tariffs, inflation, supply chains, or strategic allocations — we're in the game, not on the sidelines. And we’re loving every minute of it.

👏 Cheers to the analysts, researchers, clinicians, and innovators who make this journey both smart and soulful.

Galenus Group — Strategy with Purpose. Science with Heart.

#GalenusGroup #MarketIntelligence #GlobalStrategy #ClinicalInnovation #ProudToBuild #TeamGalenus #PurposeDriven #FinanceMeetsScience #LeadershipWithHeart

[Galenus Group @GalenusGroup]

🔬 Galenus Group – Advancing Science in Crohn’s & Ulcerative Colitis

At Galenus Group, we are deeply committed to supporting and accelerating the latest clinical advances in Inflammatory Bowel Disease (IBD) — including Crohn’s disease and ulcerative colitis.

As global science moves forward, so do we. From FDA-approved biologics to microbiome diagnostics and stem cell therapies, our research sites in Puerto Rico and Florida are actively aligning with the most promising clinical trials and therapeutic innovations.

🧪 Key Developments We Support:

✅ Mirikizumab (Omvoh) – FDA-approved (2023) for UC, showing strong efficacy in both Crohn’s and ulcerative colitis
✅ Guselkumab (Tremfya) – Approved in 2024 for moderate-to-severe UC; now under expanded global studies
✅ Mesenchymal Stem Cell Therapy – Emerging approach for immune modulation and gut healing
��� Microbiome-Based Diagnostics – Non-invasive tools using fecal microbiota profiles
✅ Genetic Research – Exploring links between Crohn’s-associated mutations and anemia
✅ Regenerative Trials – Supporting innovation in IBD tissue repair and immune reset
✅ Equity in Care – Addressing racial disparities and the financial burden on patients

🌍 We recognize IBD is a global challenge, and Galenus Group is proud to be part of a new era of research — collaborating with biotech partners, payers, and foundations to bring forward solutions that restore dignity, remission, and access.
We thank our partners for their tireless support in funding clinical progress, and we remain ready to enroll, innovate, and lead.
#GalenusGroup #IBDResearch #UlcerativeColitis #CrohnsDisease #Mirikizumab #Tremfya #StemCellTherapy #Microbiome #Genetics #GlobalHealth #ClinicalTrials #RegenerativeMedicine #HealthEquity #PrecisionCare #FloridaSites #GastroenterologyInnovation

[Galenus Group @GalenusGroup]

🧬 CAR NK Cell Therapy – Galenus Group Embraces the Next Frontier in Immuno-Oncology

At Galenus Group, we are proud to align with global leaders in cellular innovation as we advance the use of CAR NK cell therapy — a revolutionary immunotherapy that enhances the body’s innate ability to fight cancer and immune disorders.

CAR NK therapy works by attaching chimeric antigen receptors (CAR) to natural killer cells (NK cells), empowering them to detect and attack cancer cells that once evaded the immune system.

💡 Why It Matters
Originally studied in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma, this therapy is now being explored for:
🔹 Breast cancer
🔹 Ovarian and pancreatic cancer
🔹 Renal cell carcinoma
🔹 Glioblastoma & osteosarcoma
🔹 Acute myeloid leukemia (AML)
🔹 Multiple myeloma
🔹 Autoimmune diseases such as lupus and systemic sclerosis

🩸 Off-the-Shelf Innovation
Unlike CAR T therapy, CAR NK therapy is prepared from donated umbilical cord blood, allowing for hundreds of doses from a single donation — frozen and ready-to-use when patients need it most.
💉 Two Phases, Rapid Action
Pre-treatment chemotherapy clears immune space.
A single infusion of CAR NK cells then enters the body to hunt cancer.
🔬 Results So Far
73% of patients responded in early trials.
Many achieved complete remission with minimal side effects.

Follow-up data shows durable remission up to 12 months post-treatment.
🚀 What’s Next?

CRISPR-engineered NK cells

Multi-target therapies

Outpatient administration models

Drug-NK cell combinations for even greater precision

At Galenus Group, we are ready to support biotech partners and expand access to next-generation cell therapies across Florida and Puerto Rico, accelerating both discovery and delivery.

#GalenusGroup #CellTherapy #CARNK #ImmunoOncology #CRISPR #ClinicalResearch #BiotechPartnerships #CancerInnovation #Lupus #AutoimmuneResearch #SolidTumors #NKCells #ClinicalResearch #OncologyLeadership

[Galenus Group @GalenusGroup]

🚀 Galenus Group – Advancing Precision Health with Purpose
At Galenus Group, we are more than a clinical research network — we are a health innovation engine transforming managed care, biotech integration, and digital screening into scalable solutions for global impact.
🏥 Our medical group consistently ranks among the top performers in health risk management and utilization management, delivering measurable value to payers and partners.

🔬 What We Do

Longevity & Preventive Health Programs integrating metabolic, cognitive, and genomic data

Metabolic and cognitive screening powered by AI, using Neurotrack QuantFlo™ for early detection and scalable intervention

Advanced trials in cell therapies, including CAR-T and CAR-NK for immune diseases and cancer

Leading recruitment and performance in MASH/NASH and IBD studies

Custom KPI dashboards integrating clinical, financial & regulatory data

Strategic support for biotech firms in regulatory enablement & site scalability

🧬 Our Longevity Platform combines AI-enhanced diagnostics, precision risk modeling, and age-reversal strategies to extend healthspan and vitality.

🤝 Current Collaborators Include:
Novartis • Akero • Lilly • Metacrine • Regeneron • Delfi Diagnostics • Boston Pharmaceuticals • Inventiva and more.

📊 Trusted by Payers Like:
UnitedHealthcare and Aetna, delivering results through utilization and risk management at scale.
🌍 We are building the future of clinical excellence — integrating data, purpose, and personalized care.

#GalenusGroup #LongevityMedicine #PrecisionHealth #AIinHealthcare #ClinicalResearch #ManagedCare #CellTherapy #DigitalScreening #UtilizationManagement #RiskStratification #BiotechIntegration #ValueBasedCare @agostoresearch

[GSK @GSK]

For #Investors: At the Meet the Management event, our leaders will discuss the next wave of R&D at GSK - showing how our deep expertise in immune science, advanced tech and strategic partnerships are paving the way for new and better innovation to deliver growth at scaleFor #Investors: At the Meet the Management event, our leaders will discuss the next wave of R&D at GSK - showing how our deep expertise in immune science, advanced tech and strategic partnerships are paving the way for new and better innovation to deliver growth at scaleFor #Investors: At the Meet the Management event, our leaders will discuss the next wave of R&D at GSK - showing how our deep expertise in immune science, advanced tech and strategic partnerships are paving the way for new and better innovation to deliver growth at scaleFor #Investors: At the Meet the Management event, our leaders will discuss the next wave of R&D at GSK - showing how our deep expertise in immune science, advanced tech and strategic partnerships are paving the way for new and better innovation to deliver growth at scale.

[Amgen 🧪🔬🧬 @Amgen]

Amgen's scientists are pushing the boundaries of innovation, leveraging expertise from the world's best, including Nobel laureates.

Discover work from Christy Tinberg, cited by this year’s Chemistry Nobel winner, David Baker.

Read more here: 🔗 https://t.co/yAQFaQ9uU7

[Galenus Group @GalenusGroup]

@paulabadosa Vamos!

[Galenus Group @GalenusGroup]

@paulabadosa @CincyTennis Vamos Guerrera!

[Genetic Engineering & Biotechnology News @GENbio]

Gene Therapies Tested in Human Liver System in the Lab

The results highlight the potential of using whole liver perfusion systems to evaluate early stage AAV-based therapies. Learn more: https://t.co/qJqOuapfVf

[Genetic Engineering & Biotechnology News @GENbio]

Cell Therapy for Drug-Resistant Epilepsy a Preclinical Success

Neurona Therapeutics and UCSF researchers have developed a cell therapy alternative to treat the most common type of focal epilepsy. Read more: https://t.co/0obyf6Zp8N

[Galenus Group @GalenusGroup]

@paulabadosa Vamos

[Galenus Group @GalenusGroup]

@carlosalcaraz @CincyTennis Vamos!

[Galenus Group @GalenusGroup]

@carlosalcaraz @EqueliteFerrero Vamos!